BICX - BioCorRx Inc.
| Previous Close | 5.72 |
| Open | 5.72 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 5.72 - 5.72 |
| 52 Week Range | 0.04 - 8.49 |
| Volume | 175 |
| Avg. Volume | 2,808 |
| Market Cap | 14.871M |
| Beta (3Y Monthly) | 3.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.60 |
| Earnings Date | Nov 14, 2018 - Nov 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.13 |
- ACCESSWIRE•12 days ago
Uptick Newswire Hosts BioCorRx Inc. on the Stock Day Podcast to Discuss Major Company Updates
PHOENIX, AZ / ACCESSWIRE / April 10, 2019 / Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique ...
- GlobeNewswire•18 days ago
Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc.
ANAHEIM, CA, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that Joseph J. Galligan has been appointed as senior advisor to the Company. Mr. Joseph John Galligan, CFA was formally an Executive Vice President and Portfolio Manager at DoubleLine Capital LP, an investment firm with over $100 billion in assets under management, where he was one of the five founding partners. Previously, Mr. Galligan served as Senior Vice President of Apex Mortgage Capital Inc. He was also a Managing Director and Portfolio Manager at The TCW Group, Inc. Mr. Galligan held senior roles at Smith Barney, First Boston, and Scudder Stevens & Clark.
- GlobeNewswire•20 days ago
BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share
ANAHEIM, CA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced the Company completed a private placement, whereby it issued 400,000 common stock shares at a price of $15.00 per share, for total proceeds of $6 million. The $15.00 price paid by two investors, one of whom is Louis Lucido, a Director, represents a 282% premium to the market price of $3.93 per share, as of the market close on April 1, 2019. A portion of the capital will be used to fund the launch and expansion of the Company’s weight loss program in the upcoming months and to further its product development pipeline in the addiction treatment field.
- GlobeNewswire•25 days ago
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse disorders, today announced that the Company’s subsidiary, BioCorRx Pharmaceuticals, will exhibit at the American Society of Addiction Medicine (ASAM) 50th Annual Conference on April 4th through the 7th, at the Hilton Hotel in Orlando, Florida.
- GlobeNewswire•26 days ago
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement
Brady Granier, President, CEO and Director, stated, “We appreciate Dr. Brar’s guidance and expertise which has been extremely valuable as we continue to move forward with our plans for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders, as well as other products in our pipeline. Dr. Brar, Senior VP of Drug Development, commented, “I look forward to helping further advance and accelerate the regulatory approval process for BICX102.
- GlobeNewswire•last month
BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019
ANAHEIM, CA, March 14, 2019 -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use.
- GlobeNewswire•2 months ago
BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder
ANAHEIM, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has engaged IRISYS, LLC, a contract pharmaceutical product development and manufacturing services company, for the development and manufacturing of BICX102, a multi-month sustained release naltrexone implant. The Company plans to conduct clinical trials and seek FDA approval for BICX102 as a treatment for opioid and alcohol use disorders. “We look forward to partnering with such a reputable partner as IRISYS to manufacture our naltrexone implant,” said Brady Granier, CEO and President of BioCorRx, Inc. “Having received the National Institute on Drug Abuse grant award last month and following a pre-IND meeting we had with the FDA last year, we are now in a position to begin the manufacturing and development process for our lead pharmaceutical candidate, BICX102.
- GlobeNewswire•2 months ago
BioCorRx Appoints Two Finance Veterans to the Board of Directors
ANAHEIM, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the addition of two new independent directors, Louis Lucido and Luisa Ingargiola, to the Company’s Board of Directors. “We are delighted to welcome Lou and Luisa as new independent directors.
- PR Newswire•2 months ago
February 20th Virtual Investor Conferences Company Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , Feb. 25, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...
- GlobeNewswire•2 months ago
BioCorRx Announces Formation of Scientific Advisory Board
ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the formation of its Scientific Advisory Board (SAB) with three key appointments: David R. Gastfriend, M.D., DFASAM, Evgeny Krupitsky M.D., Ph.D., D.M.Sc., and George E. Woody, M.D.
- PR Newswire•2 months ago
Live Investor Conference & Webinar February 20th
Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Feb. 15, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming ...
- PR Newswire•2 months ago
BioCorRx Inc. to Webcast Live at VirtualInvestorConferences.com February 20th
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com ANAHEIM, Calif. , Feb. 15, 2019 ...
- GlobeNewswire•3 months ago
Uptick Newswire Hosts BioCorRx Inc’s CEO and CFO to Discuss Their Recent NIDA Grant for Their Naltrexone Implant for Opioid Use Disorder
The Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc Brady Granier and CFO Lourdes Felix talked with Stock Day’s Everett Jolly. At the start of the interview Jolly asked about the National Institute on Drug Abuse (NIDA) grant and what it would mean to the company.
- GlobeNewswire•3 months ago
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-100. The reverse split took effect at the open of business Tuesday, January 22, 2019.
- GlobeNewswire•3 months ago
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has been awarded a 2-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925 for the development of BICX102, the Company’s single administration, multi-month sustained release naltrexone implant for the treatment of opioid use disorder. The Company is seeking FDA approval for BICX102.
- GlobeNewswire•4 months ago
Brady Granier, CEO, President, and Director of BioCorRx Inc. Provides Update and Outlook in a New Audio Interview with SmallCapVoice.com
SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available. Brady Granier called in to SmallCapVoice.com, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process.
- GlobeNewswire•5 months ago
BioCorRx Provides Business Update for the Third Quarter of 2018
ANAHEIM, CA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx, Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2018. Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “We continue to work on the advancement of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. In early October, we received a Just-In-Time (JIT) request from NIDA on our grant application submitted in May of this year.